Consideraciones para la supervisión regulatoria de los ensayos clínicos en la pandemia de COVID-19, 5 de junio del 2020
Abstract
En este documento se presenta a las autoridades regulatorias nacionales orientación sobre la regulación de los ensayos clínicos a fin de promover la investigación y el uso de medicamentos y otras tecnologías sanitarias que sean seguros y eficaces para satisfacer las necesidades de salud durante la pandemia de COVID-19.
Collections
This notice should be preserved along with the article's original URL.Attribution-NonCommercial-ShareAlike 3.0 IGO
Related items
Showing items related by title, author, creator and subject.
-
Clinical trials on drug repositioning for COVID-19 treatment
(2020-03)[ABSTRACT]. The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were ... -
Adherence to clinical trial registration in countries of Latin America and the Caribbean, 2015
(2018-02)[ABSTRACT]. Objective. To determine the prevalence of clinical trial registration in the International Clinical Trial Registry Platform (ICTRP) for studies from Latin America and the Caribbean (LAC) and to identify the key ... -
The landscape of COVID-19 clinical trials in Latin America and the Caribbean: assessment and challenges
(2020-12-21)[ABSTRACT]. A considerable number of clinical trials is being conducted globally in response to the COVID-19 pandemic, including in low- and middle-income countries such as those in the Latin America and Caribbean region ...
